Evaluation of Berberis vulgaris Phytochemicals for Targeting PIM1 Kinase in Prostate Cancer: An In silico Approach
Published: 2024-03-07
Page: 60-72
Issue: 2024 - Volume 7 [Issue 1]
Mudassir Alam
*
Department of Zoology, Aligarh Muslim University, Aligarh, (202002), India.
Kashif Abbas
Department of Zoology, Aligarh Muslim University, Aligarh, (202002), India.
Mohd Tanjeem Raza
Department of Zoology, Aligarh Muslim University, Aligarh, (202002), India.
Hameim Yahya
Department of Zoology, Aligarh Muslim University, Aligarh, (202002), India.
Mohd Faizan Saifi
Department of Zoology, Aligarh Muslim University, Aligarh, (202002), India.
Shakir Kamal
Department of Biotechnology, Aligarh Muslim University, Aligarh, (202002), India.
*Author to whom correspondence should be addressed.
Abstract
Background: PIM1 kinase is a serine/threonine kinase known for its excessive production in various human cancers, particularly prostate cancer. This enzyme promotes prostate cancer development by adding phosphate groups to cellular components, preventing programmed cell death (apoptosis), and facilitating cell cycle progression. Thus, PIM1 kinase could serve as a therapeutic target for the treatment of prostate cancer. Phytochemicals present in Berberis vulgaris possess anti-cancerous properties. Current study investigated the phytochemicals present in Berberis which could inhibit PIM1 kinase, thus serving as a drug candidate.
Methods: In this study, various computational tools were employed to assess the potential of phytochemicals present in the root extract of B. vulgaris. The work employed computational tools- molecular docking, pharmacokinetics, ADME, toxicity, and biological activity prediction to elucidate top potent phytochemicals.
Results: The computational analysis revealed promising potential in the phytochemicals found in B. vulgaris, particularly berberine, columbamine, isocorydine, and oxyberberine, as inhibitors of PIM1 kinases. This suggests that these root extract compounds of B. vulgaris may serve as an effective anti-cancer agent by inhibiting PIM1 kinase activity.
Conclusion: The identified compounds, berberine, columbamine, isocorydine, and oxyberberine, show promising candidates for further research and development of anti-cancer therapies targeting PIM1. They showed good docking scores and drug-likeness properties and exhibited biological activity of anticarcinogenic, antineoplastic, Pim1 kinase inhibitor, and Prostate cancer treatment.
Keywords: PIM1 kinase, berberis vulgaris, prostate cancer, phytochemicals, insilco, inhibitors
How to Cite
References
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89.
Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer. Signal Transduct Target Ther. 2020;5(1):7
Nock S, Karim E, Unsworth AJ. Pim Kinases: Important Regulators of Cardiovascular Disease. Int J Mol Sci. 2023;24(14):11582.
Markou A, Tzanikou E, Strati A, Zavridou M, Mastoraki S, Bournakis E, Lianidou E. PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients. Cancers (Basel). 2020;12(5):1188.
Pantel K, Hille C, Scher HI. Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. Clin Chem. 2019;65(1):87-99.
Eerola SK, Kohvakka A, Tammela TLJ, Koskinen PJ, Latonen L, Visakorpi T. Expression and ERG regulation of PIM kinases in prostate cancer. Cancer Med. 2021;10(10):3427-3436.
Jeyapal GP, Chandrasekar MJN, Krishnasamy R, Selvaraj J, Mohammad M, Nanjan MJ. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials. Anticancer Agents Med Chem. 2018;(8):1100-1114.
Jahan F, Alvi SS, Islam MH. Berberis aristata and its secondary metabolites: Insights into nutraceutical and therapeutical applications. Pharmacological Research - Modern Chinese Medicine. 2022;5:100184.
Neag MA, Mocan A, Echeverría J, Pop RM, Bocsan CI, Crişan G, Buzoianu AD. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Front Pharmacol. 2018;9:557.
Mustafa K, Mohamed H, Shah AM, Yu S, Akhlaq M, Xiao H, Li S, Naz T, Nosheen S, Bai X, Song Y. In Vitro Anticancer Potential of Berberis lycium Royle Extracts against Human Hepatocarcinoma (HepG2) Cells. Biomed Res Int. 2020 Oct;2020:8256809.
Koutova D, Kulhava M, Havelek R, Majorosova M, Královec K, Habartova K, Hošťálková A, Opletal L, Cahlikova L, Řezáčová M. Bersavine: A Novel Bisbenzylisoquinoline Alkaloidwith Cytotoxic, Antiproliferative and Apoptosis-Inducing Effects on Human Leukemic Cells. Molecules. 2020;25(4):964.
Samadi P, Sarvarian P, Gholipour E, Asenjan KS, Aghebati-Maleki L, Motavalli R, Hojjat-Farsangi M, Yousefi M. Berberine: A novel therapeutic strategy for cancer. IUBMB Life. 2020 Oct;(10):2065-2079.
Paudel S, Mishra N, Agarwal R. Phytochemicals as Immunomodulatory Molecules in Cancer Therapeutics. Pharmaceuticals (Basel). 2023;16(12): 1652.
Schrödinger L, DeLano W. PyMOL. 2020.
Available from:http://www.pymol.org/pymol.
O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011;3(1):1-4.
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Chem Biol Methods Protoc. 2015:243-50.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-61.
Discovery Studio Modeling Environment, Release 4.5. BIOVIA, Dassault Systèmes, San Diego; 2021.
Geete A., Damre M., Kokkula A. Drug Likeness Tool (DruLiTo) Chemistry Development Kit (CDK), Department of Pharmacoinformatics NIPER, Mohali. [(accessed on 22 July 2021)]; Available online: http://www.niper.gov.in
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original particle: S0169-409X(96)00423-1. Adv Drug Deliv Rev. 2001;46(1-3): 3-26.
Cheng F, Li W, Zhou Y, et al. AdMetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012;52 (11):3099-3105.
Banerjee P, Eckert A, Schrey AK, Preißner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257-W263.
Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV, Poroikov VV. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem Heterocycl Compd. 2014;50: 444-57.